

Reference:	FOI.21074.26
Subject:	Myelofibrosis and Stem Cell Therapy
Date of Request:	17 July 2026

Requested:

- How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)
 - Myelofibrosis (ICD10 code D47.4)
 - Polycythaemia Vera (ICD10 code D45)
 - Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005)
- How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)
 - Momelotinib
 - Fedratinib
- How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?
 - Hydroxycarbamide
 - Interferon therapy
- Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)		
Fedratinib (Inrebic)		
Momelotinib (Omjjara)		

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with some of the requested information as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding the following details under Section 40(2) of the FoIA:

- The figures in the tables for questions 1, 3 and 4 have been replaced with an asterisk (*) due to the low number of cases (less than 5)

It is not within the expectation of these individuals that their personal data would be released into the public domain. This information is classed as personal data of a third party. Therefore, it is being withheld in accordance with the exemption set out in section 40(2) of the FoIA, by virtue of section 40(3)(a) of the FoIA, which permits a public authority to withhold personal data other than the requestor's where the disclosure would breach Data Protection principles.

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

However, whilst operating in accordance with the Section 45 Freedom of Information Code of Practice, the UHB has a duty to provide advice and assistance and provides the accessible information it holds below.

1. The UHB provides within the table below, the number of patients initiated on Ruxolitinib (Jakavi), for the listed conditions, during the period 1 January to 30 June 2026.

Condition	Number
Myelofibrosis	*
Polycythaemia Vera	0
Graft vs Host Disease	0

2. The UHB confirms zero (0) patients were initiated with the listed regimens for any condition, during the period 1 January to 30 June 2026
3. The UHB provides within the table below, the number of patients diagnosed with Polycythaemia Vera that were treated with the listed medications, during the period 1 January to 30 June 2026.

Medication	Number
Hydroxycarbamide	14
Interferon therapy	*

4. The UHB provides within the table below, the number of patients receiving the listed treatments, split by systemic therapy type, during the period 1 January to 30 June 2026.

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	*	*
Fedratinib (Inrebic)	0	*
Momelotinib (Omijara)	0	*